Human Mesenchymal Stem Cells For Infants At High Risk For Bronchopulmonary Dysplasia
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study is an open-label, single-center, dose escalation study to evaluate of safety and
efficacy of human umbilical cord -derived mesenchymal stem cells (hUC-MSCs) in premature
infants at high risk for Bronchopulmonary Dysplasia（BPD）
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Children's Hospital of Chongqing Medical University